Recent Updates
Recently added Catalysts

Upcoming Catalyst

Drug Pipeline Intelligence

Clinical Trial Results

Inside Trades

Options Data

News Section

Hedge Funds

Ownership Trends

Competitive Position

Thermo Fisher Scientific Inc

$527.05

+2.34 (+0.45%)

C 42Pipeline Score Tools & Services · Commercial
Market Cap
166.59 B
EPS
18.21
P/E Ratio
24.65 $
Value Trade
916.92 M
SEC Financials
Q1 2026

  • Dilution Risk

    5%

  • Revenue

    11.01 B

  • R&D Expenses

    336.00 M

  • Operating CF

    1.19 B

  • Total Assets

    113.28 B

  • Total Liabilities

    113.28 B

  • Equity

    51.93 B

  • D/E Ratio

    12,345

0.96 %
Week
-14.88 %
1 Month
-12.22 %
3 Month
-21.77 %
6 Month
-4.13 %
5 Year
35,528.45 %
All Time
Cash Data
Profitable

  • Cash Position

    3.28 B

  • Monthly Burn

    -

  • Runway

    12,345 mo

  • Burn Trend

    Stable

  • SEC Filing

    May 1, 2026
Overview
Volume
1.23 M
52 Week Range
385.46 - 643.99
% held by Insiders
0.24 %
% held by Institutions
93.88 %
Enterprise Value
206.62 B
Total Shares
371.70 M
Short %
1.44 %
Float Shares
371.32 M
Company Description
HQ: 168 THIRD AVENUE, WALTHAM, MA,...
Employees:125,000
https://www.thermofisher.com

locked

Upcoming Catalyst
Catalyst Drug/Treatment Stage Probability of Approval Description Drug Type Therapeutic Area Source
PDUFA 2026
Example Drug Treatment for example condition requiring FDA review
Phase 3
-%

FDA review of the new drug application for the treatment of example condition.

Read More
Small Molecule
Oncology
Example Drug Treatment for example condition requiring FDA review
Phase 3
-%

FDA review of the new drug application for the treatment of example condition.

Read More
Small Molecule
Oncology
Example Drug Treatment for example condition requiring FDA review
Phase 3
-%

FDA review of the new drug application for the treatment of example condition.

Read More
Small Molecule
Oncology
Unlock Upcoming Catalyst data
Drug Pipeline Intelligence
C42
Pipeline Score
$1.2B
Pipeline Value
Valuation Signal
5
Drugs Scored
0.0x
rNPV / MCap
Top 60%
Large Pharma
(rank 366 of 912)
Percentile Rank
Thermo Fisher Scientific Inc carries a moderate pipeline score (42/100), with $1.2B risk-adjusted pipeline value, led by zamtocabtagene autoleucel in B-Cell Neoplasm (Phase 2), across $72B in total addressable markets.
Showing 1 of 1 assets
DrugIndicationPhaseNCT IDPTRSrNPVStatusEnrollmentVelocityDesignCompletionML SignalLast Change
zamtocabtagene autoleucel
Small molecule		B-Cell NeoplasmPhase 2NCT0650893119% $387M RECRUITING 31 AVERAGE D (28) Dec 31, 2029 -
May 21, 2026
Unlock Drug Pipeline Intelligence
Clinical Trial Results
Drug Name Indications Phase Date Trial Results Summary Title Source
Example Drug
Example indication for clinical evaluation
Phase 3
2025-12-01

The study met its primary endpoint demonstrating statistically significant improvement.

Read More

Phase 3 Study Results Announcement

Example Drug
Example indication for clinical evaluation
Phase 3
2025-12-01

The study met its primary endpoint demonstrating statistically significant improvement.

Read More

Phase 3 Study Results Announcement

Example Drug
Example indication for clinical evaluation
Phase 3
2025-12-01

The study met its primary endpoint demonstrating statistically significant improvement.

Read More

Phase 3 Study Results Announcement

Unlock Clinical Trial Results data
Inside Trades
TREND
CORPORATE INSIDERS BOUGHT SHARES WORTH 1.8M IN THE LAST 3 MONTHS
YEARLY INSIDER TRANSACTIONS
Sector Avg.
INSIDERS
SOLDINSIDERS
BOUGHT
POSITIVE SENTIMENT Based on 22 Insiders Transactions
Unlock Inside Trades data
Show Data
Hedge Funds
TREND
HEDGE FUNDS INCREASED HOLDINGS BY 200.0K SHARES IN THE LAST QUARTER
Shares Held
2040.00B1530.00B1020.00B510.00B0
Q3
2024
Q4
2024
Q1
2025
Q2
2025
HEDGE FUNDS
SOLDHEDGE FUNDS
BOUGHT
POSITIVE SENTIMENT Based on 27 hedge funds in the last quarter
18 buying (3 new)·9 selling (1 exited)·2 unchanged
Fund Count
60%
Share Volume
25%
Conviction
15%
Hedge Funds invested in TMO
HedgeFund Name
( 3 )
% of Portfolio Current MV
-
Shares Owned
-
Activity
Avg Price $0

Example Capital Management

2.5 %
15.00 M
250.00 K

Example Capital Management

2.5 %
15.00 M
250.00 K

Example Capital Management

2.5 %
15.00 M
250.00 K
Unlock Hedge Funds table data
TMO Institutional Ownership Trends
Current Insider %
5.20%
—+0.00%
Current Institutional %
62.40%
—+0.00%
Total Ownership
67.60%
Insider + Institutional
Data Points
1
1 Ticker(s)
Option Chain Statistics
ExpirationVolumeOpen InterestImplied Volatility CallsImplied Volatility Puts
CallsPutsPut-Call RatioCallsPutsPut-Call RatioIVOiWaIvVWaIvIVOiWaIvVWaIv
2026-07-170 0.00 0 0 - - - - - -
2026-07-170 0.00 0 0 - - - - - -
2026-07-170 0.00 0 0 - - - - - -
Unlock Option Chain Statistics data
Option Chain
CallsStrikePuts
Last PriceVolumeOpen InterestLast PriceVolumeOpen Interest
No data available
Unlock Option Chain data
Unlock Options Chart data
Open interest
0 600K 1.2M 1.8M Avg OI 1.00 M Open Interest
0 1 2 3 1.1 Put-Call Ratio
Today's Open Interest
1.00 M
Put-Call Ratio
1.1
Put Open Interest
480.00 K
Call Open Interest
520.00 K
Open Interest Avg (30-day)
900,000
Today vs Open Interest Avg (30-day)
11.11%
Option Volume
0 450K 900K 1.4M Avg OV 750.00 K Option Volume
0 1 2 3 0.95 Put-Call Ratio
Today's Volume
750.00 K
Put-Call Ratio
0.95
Put Volume
360.00 K
Call Volume
390.00 K
Volume Avg (30-day)
800,000
Today vs Volume Avg (30-day)
-6.25%
Company News
Competitive Position
How TMO ranks across every disease it competes in
Competitive Position is a premium feature
See how TMO ranks against every competitor across each disease it develops in: phase, best drug, trials and likelihood of approval.
Start free trial